Document Detail

Kinetics of both leukemic and normal cell population reduction following 5-azacytidine.
MedLine Citation:
PMID:  50128     Owner:  NLM     Status:  MEDLINE    
The cytotoxic effect of 5-azacytidine (AzaCR) on normal hematopoietic colony-forming units (NCFU) and L1210 leukemic colony-forming units (LCFU) in the femoral marrow of BALB/c x DBA/2 F1 mice was studied using the spleen colony assay. Dose-survival curves for LCFU and NCFU were biphasic. Repopulation of LCFU was rapid at a low dose of AzaCR (0.1 mg/mouse) but was delayed for greater than 6 days at higher doses (0.25 mg/mouse and above). Of the agents tested in this system, only AzaCR exhibited these properties. Survival of mice with L1210 leukemia following AzaCR administration was prolonged beyond that predicted by the degree of LCFU reduction alone, and reflected the delay in LCFU repopulation. In contrast, repopulation of NCFU in normal mice was not delayed at a high dose of AzaCR (0.5 mg/mouse). AzaCR produced a nine-fold greater reduction of NCFU in leukemic mice than in normal mice, measured 5 days after AzaCR injection. While divided doses of AzaCR produced LCFU cytotoxicity equivalent to a single dose, 24-hr infusions of high doses were inferior to single infections.
C A Presant; T Vietti; F Valeriote
Related Documents :
2036248 - Predicted dose-volume isoeffect curves for stereotactic radiosurgery with the 60co gamm...
19634438 - Phosphorus fractions and its release in the sediments of haihe river, china.
18642928 - Distribution of trichothecenes, zearalenone, and ergosterol in a fractionated wheat har...
1612968 - Pulsed brachytherapy: the conditions for no significant loss of therapeutic ratio compa...
19221978 - Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately...
14529938 - Evaluation of relative anti-myeloma activity of high-dose melphalan followed by the fir...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer research     Volume:  35     ISSN:  0008-5472     ISO Abbreviation:  Cancer Res.     Publication Date:  1975 Aug 
Date Detail:
Created Date:  1975-10-30     Completed Date:  1975-10-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  2984705R     Medline TA:  Cancer Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1926-30     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Azacitidine / pharmacology,  therapeutic use*,  toxicity
Bone Marrow / drug effects
Bone Marrow Cells
Dose-Response Relationship, Drug
Hematopoietic Stem Cells / drug effects*
Leukemia L1210 / drug therapy*
Mice, Inbred BALB C
Mice, Inbred DBA
Time Factors
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical trial of bleomycin (NSC-125066) in the treatment of metastatic renal carcinoma.
Next Document:  Binding of bleomycin to DNA in bleomycin-sensitive and -resistant rat ascites hepatoma cells.